REDUCER SYSTEM

The coronary sinus reducer: clinical evidence and technical aspects

Francesco GianniniAndrea AurelioRichard J. JabbourLuca FerriAntonio Colombo & Azeem Latib

Pages 47-58 | Received 26 Sep 2016, Accepted 07 Dec 2016, Accepted author version posted online: 09 Dec 2016, Published online: 15 Dec 2016

ABSTRACT

Introduction: Chronic refractory angina is often a disabling condition, predominantly due to severe obstructive coronary artery disease, that is inadequately controlled by optimal medical therapy and not amenable to further percutaneous or surgical revascularization. mortality rates associated with this condition are relatively low in clinically stable patients. however, it is associated with a high hospitalization rate and a reduction in both exercise capacity and quality of life. due to the paucity of available treatment options, there is an unmet need for new therapies for these patients and for a reduction in the associated economic healthcare burden.

Areas covered: This review is focusing on the clinical evidence and technical aspects of this new therapeutic modality in refractory angina patients unsuitable for revascularization.

Expert commentary: The Coronary Sinus Reducer (Neovasc Inc. Richmond B.C., Canada) is a new percutaneous device designed to achieve a controlled narrowing of the coronary sinus that may alleviate myocardial ischemia, possibly by redistributing blood from the less ischemic sub-epicardium to the more ischemic sub-endocardium, or by neoangiogenesis. Recently, a randomized, double-blind, multi-center clinical trial demonstrated a benefit in improving symptoms in 104 refractory angina patients, when compared to placebo.

KEYWORDS: Coronary sinus reducer implantationrefractory anginacoronary artery diseaseangina pectorismyocardial ischemia

Acutus Medical® Announces First Patient Procedure in Pivotal Atrial Fibrillation Trial – UNCOVER-AF

RELEASE ACUTUS MEDICAL INC.

Acutus Medical Inc. ha annunciato il completamento della prima procedura sul primo paziente per lo studio clinico “Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation” (UNCOVER-AF).Lo studio valuterà l’incidenza del dispositivo e la sicurezza della procedura, l’efficacia e l’efficienza dell’utilizzo del sistema AcQMAP, Sistema di imaging e mappatura ad alta risoluzione nella guida dell’ablazione in pazienti affetti da fibrillazione atriale persistente (AF).

I pazienti sono al momento arruolati per lo studio clinico UNCOVER-AF in centri di eccellenza in Europa e Canada. La prima procedura è stata completata con successo dal Dr. Andrew Grace, presso il Papworth Hospital a Cambridge, Inghilterra.

3° TAVI PARMA

ENDOTECH SPA sarà sponsor dell’evento:

3°TAVI PARMA

Impianto percutaneo della Valvola Aortica e Riparazione Valvola Mitralica

Data: 29 MAGGIO 2015

Luogo: FONDAZIONE MAGAGNI ROCCA – Mamiano di Traversolo, Parma

 

NEOVASC REDUCER

LOGO-NEOVASC

 

 

Vancouver, BC, Canada – 19 Marzo 2015- Neovasc Inc. ( NASDAQ:NVCN) (TSX:NVC) ha annunciato che il sistema Neovasc Reducer™ è stato introdotto in alcuni centri Italiani selezionati.

I primi casi italiani sono stati eseguiti presso l’Ospedale San Raffaele di Milano dal Dr. Antonio Colombo, Responsabile del Reparto di Cardiologia Interventistica ed Emodinamica e presso l’Azienda Ospedaliera Bolognini di Seriate dal Dr. Alfonso Ielasi presso il reparto di Cardiologia , Unità Coronarica diretta dal Dr. Maurizio Tespili

reducer